PUMA BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.95 USD | -2.32% |
|
-9.51% | -31.87% |
| Jul. 01 | Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Value Index | CI |
| Jul. 01 | Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Completeness Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 340.9 | 408 | 124.3 | 196 | 206 | 142.3 | - | - |
| Enterprise Value (EV) 1 | 324.2 | 412.9 | 158.3 | 196 | 206 | 142.3 | 142.3 | 142.3 |
| P/E ratio | -4.49 x | -6.75 x | -4.22 x | - | 9.62 x | 12.2 x | 12.1 x | 9.22 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.25 x | 1.81 x | 0.49 x | 0.86 x | 0.87 x | 0.65 x | 0.63 x | 0.62 x |
| EV / Revenue | 1.25 x | 1.81 x | 0.49 x | 0.86 x | 0.87 x | 0.65 x | 0.63 x | 0.62 x |
| EV / EBITDA | -10,989,610 x | -20,028,600 x | 10,455,282 x | 6,009,876 x | - | - | - | - |
| EV / FCF | 15.4 x | 561 x | 6.02 x | -8.59 x | 7.67 x | 3.16 x | 3.03 x | 3.31 x |
| FCF Yield | 6.47% | 0.18% | 16.6% | -11.6% | 13% | 31.6% | 33% | 30.2% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 38,961 | 39,762 | 40,886 | 46,346 | 47,571 | 48,239 | - | - |
| Reference price 2 | 8.750 | 10.26 | 3.040 | 4.230 | 4.330 | 2.950 | 2.950 | 2.950 |
| Announcement Date | 2/20/20 | 2/25/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 272.3 | 225.1 | 253.2 | 228 | 235.6 | 219 | 225 | 229.8 |
| EBITDA | -31.02 | -20.37 | 11.89 | 32.62 | - | - | - | - |
| EBIT 1 | -39.1 | -30.4 | 1.3 | 23.7 | 32.6 | 21.35 | 25.05 | 24.5 |
| Operating Margin | -14.36% | -13.51% | 0.51% | 10.39% | 13.84% | 9.75% | 11.13% | 10.66% |
| Earnings before Tax (EBT) 1 | -75.6 | -59.8 | -28.8 | 0.5 | 22.7 | 13.9 | 5.5 | - |
| Net income 1 | -75.6 | -60 | -29.1 | - | 21.6 | 10.25 | 15.1 | 15.55 |
| Net margin | -27.76% | -26.65% | -11.49% | - | 9.17% | 4.68% | 6.71% | 6.77% |
| EPS 2 | -1.950 | -1.520 | -0.7200 | - | 0.4500 | 0.2420 | 0.2430 | 0.3200 |
| Free Cash Flow 1 | 22.07 | 0.727 | 20.65 | -22.83 | 26.87 | 45 | 47 | 43 |
| FCF margin | 8.11% | 0.32% | 8.16% | -10.01% | 11.4% | 20.55% | 20.88% | 18.71% |
| FCF Conversion (EBITDA) | - | - | 173.7% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 124.39% | 439.02% | 311.26% | 276.53% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 2/25/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 55.4 | 45.7 | 59.5 | 57.1 | 65.7 | 52.8 | 54.6 | 56.1 | 72.2 | 43.77 | 47.3 | 57.85 | 70.1 |
| EBITDA | - | - | - | 4.62 | - | - | 7.768 | - | - | - | - | - | - |
| EBIT 1 | 6.8 | -0.7 | 12.1 | 2.393 | 10 | 4.4 | 4.9 | 8.6 | 14.8 | -2.299 | -4.3 | 8.35 | 19.6 |
| Operating Margin | 12.27% | -1.53% | 20.34% | 4.19% | 15.22% | 8.33% | 8.97% | 15.33% | 20.5% | -5.25% | -9.09% | 14.43% | 27.96% |
| Earnings before Tax (EBT) 1 | 4.4 | -3.4 | 9.5 | -0.293 | -5.3 | 1.6 | 2.3 | 6 | 12.8 | -4.595 | -6.7 | 9.1 | 16.1 |
| Net income 1 | 4.2 | -3.4 | 9.4 | -0.36 | -5.6 | 1.4 | 2.1 | 5.8 | 12.3 | -4.815 | -6.5 | 5.35 | 16.2 |
| Net margin | 7.58% | -7.44% | 15.8% | -0.63% | -8.52% | 2.65% | 3.85% | 10.34% | 17.04% | -11% | -13.74% | 9.25% | 23.11% |
| EPS 2 | 0.1000 | -0.0800 | 0.2100 | -0.0100 | -0.1200 | 0.0300 | 0.0500 | 0.1200 | 0.2600 | -0.1000 | -0.0497 | 0.1250 | 0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/2/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/29/24 | 5/2/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 4.92 | 34 | - | - | - | - | - |
| Net Cash position | 16.7 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.2416 x | 2.857 x | - | - | - | - | - |
| Free Cash Flow 1 | 22.1 | 0.73 | 20.7 | -22.8 | 26.9 | 45 | 47 | 43 |
| ROE (net income / shareholders' equity) | -292% | -1,042% | - | 123% | - | - | - | - |
| ROA (Net income/ Total Assets) | -30.6% | -25% | -12.4% | - | - | - | - | - |
| Assets 1 | 247 | 239.6 | 235.2 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | 0.0200 | 0.5100 | -0.3500 | - | - | - | - |
| Capex | 0.31 | 0.05 | - | - | - | - | - | - |
| Capex / Sales | 0.11% | 0.02% | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 2/25/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2.95
USD
Average target price
4.333
USD
Spread / Average Target
+46.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.87% | 142M | |
| +18.97% | 45.34B | |
| +41.98% | 40.42B | |
| -10.06% | 37.92B | |
| +31.15% | 31.75B | |
| -7.79% | 27.71B | |
| +13.32% | 26.52B | |
| +43.05% | 13.96B | |
| +31.28% | 12.44B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- PBYI Stock
- Financials Puma Biotechnology, Inc.
